⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IFRX News
InflaRx N.V. Common Stock
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
globenewswire.com
IFRX
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
globenewswire.com
IFRX
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
prnewswire.com
SNY
JSPR
IFRX
REGN
NVS
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
globenewswire.com
IFRX
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
globenewswire.com
IFRX
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
globenewswire.com
IFRX
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
globenewswire.com
IFRX
InflaRx to Report First Quarter 2026 Results on May 7, 2026
globenewswire.com
IFRX
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
globenewswire.com
IFRX
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
globenewswire.com
IFRX